Document is current
Any future updates will be listed below
-
Authors
Angelini Stewart, Ariella https://orcid.org/0009-0004-4819-5609
Ahrens-Nicklas, Rebecca C.
Tsai, Shengdar Q. https://orcid.org/0000-0001-9161-3993
Musunuru, Kiran https://orcid.org/0000-0003-3298-0368
Giannikopoulos, Petros https://orcid.org/0000-0003-4342-1756
Clelland, Claire D. https://orcid.org/0000-0002-9112-2278
- License Information
-
More Information
Article History
Received: 24 June 2025
Accepted: 23 October 2025
First Online: 24 November 2025
Competing interests
: C.D.C. is a founder with equity in Ciznor, a gene therapy company. R.C.A.-N. is an advisor to Latus Bio and AskBio. K.M. is an advisor to and holds equity in Verve Therapeutics and Variant Bio, is an advisor to Lexeo Therapeutics and Capstan Therapeutics and receives research funding from Nava Therapeutics and Beam Therapeutics. S.Q.T. holds patents for GUIDE-seq (US 9,822,407 B2), CIRCLE-seq (US 9,850,484 B2) and CHANGE-seq (US 10,920,272 B2) and has filed a patent application on CHANGE-seq-R. S.Q.T. is a member of the scientific advisory boards of Prime Medicine and Ensoma. P.G. is a cofounder and director of Need and a consultant for IMDPath and ResearchDx. All other authors report no conflicts of interest.
